Company Name:Abcam

Stock Market: FTSE 250 (LSE: ABC)
Industry Sector: Retail (Catalogue & Mail Order)
Market Capitalisation: £192.87 million (as of 26 February 2009)
Yearly Revenue: £36.69 million (as of 30 June 2008)
Operating Income: £7.9 million (as of 30 June 2008)
Net Income: £5.89 million (as of 30 June 2008)
Total Assets: £23.8 million (as of 30 June 2008)

Key People: Jonathan Milner (CEO and Executive Director), Jeffrey Iliffe (CFO and Executive Director), Tom McGuire (Secretary), David Cleevely (Chairman)
Headquarters Address: 332 Cambridge Science Park, Milton Road
Cambridge CB4 0FW, United Kingdom

Number of Employees: 184
Website Address: www.abcam.com

Company Overview
Abcam (the ‘Company’) is a United Kingdom-based company and together with its subsidiaries, they are all engaged in the development, selling, and marketing of antibodies and other products. The Company sells their products through the Internet to customers worldwide. Abcam operates through its subsidiaries, which include Abcam KK and Abcam Inc. Both subsidiaries are involved with the activities involving selling and distribution of antibodies. The Company operates in several countries, including Japan, the United States of America, and the United Kingdom.

The Company is a distributor and producer of antibodies and other products. Abcam’s vision is to produce and ensure the best quality and largest online antibody resource available commercially. The Company currently has 44,000 products and it is continually adding products. Abcam had enormous success in attracting skilled people to their business. This high level of human resources increases the capabilities of other employees to make the company more successful. The employees are all dedicated, and fully committed to their work to further develop their products in the existing market.

The scope of products by research area includes cancer, cell biology, developmental biology, microbiology, immunology, cardiovascular, chromatin, neuroscience, signal transduction, nuclear signalling, and stem cells. The products by type are proteins, loading controls, lysates, tools and reagents, primary and secondary antibodies, isotope controls, peptides, slides, and tags and cell markets. The primary objective of the Company is to provide high quality antibodies against many proteins targets. Every antibody undergoes thorough research and testing before products are introduced to the market. Solidstatestorage.co.uk is great for buying an ssd drive.

Current Financial Overview
As of the fiscal year ending 30 June 2008, the Company incurred total revenue of £36.69 million compared to the fiscal year ending 2007, which is £24.51 million. Operating income increased from £5.8 million in 2007 to £7.3 million in 2008. Net income was amounted to £5.89 for 2008 and £4.06 million in 2007. Sales increased by 49.75% from £36.7 million in 2007 to £49.1 million in 2008. The increase is due to the constant currency basis. The gross margin also increased from the previous review with 59.1% to 60.8% at present. The increase is due to improved pricing. The administrative expenses grew from £7.7 million in 2007 to £12.5 million in 2008. Research and development expenditures had an increased of 39.8%.

The Company is looking forward to increase its own manufacturing capabilities through continued investment in a high-throughput production (HTP) laboratory. The group’s activities involve exporting and importing its products across international borders. Abcam faces competition and different strategic risks to compete with the international market as well as to further developed its existence in the present market and potential customers.